Earendil Labs Announces Research Collaboration with Genentech to Discover and Develop Therapeutic Bispecific Antibodies in Oncology October 1, 2026
IDMC Recommends Continued Ph 2 Development of IMNN-001 Following Favorable Safety Review October 1, 2026
Results Announced for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Ph 3 EXCALIBER-RRMM Trial in RRMM Patients October 1, 2026
AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance ADC combination strategy in cancer October 1, 2026
FDA Approves Lyrfigtu (Lirafugratinib) for 2L Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment Option October 1, 2026
Henlius and Amberstone Partner to Develop Next-Generation Conditionally Activated TCEs for Solid Tumours October 1, 2026
InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines October 1, 2026
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015 October 1, 2026
Nature Medicine Publication of ASPEN-06 Ph 2 Data Demonstrates Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer October 1, 2026
New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line RRMM October 1, 2026
VERSATILE-002 Ph 2 Results of PDS0101 + pembrolizumab in HPV16+ve Recurrent and/or Metastatic (R/M) Head & Neck Cancer published in JAMA Oncology October 1, 2026
Final OS results from randomized Ph 2 OVATION 2 Study of IMNN-001 in IL advanced ovarian cancer October 1, 2026
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line RRMM October 1, 2026
SOT106 granted fast Track Designation in osteosarcoma and orphan Drug Designation granted in soft tissue sarcoma October 1, 2026
Ifinatamab Deruxtecan BLA for Certain Patients with Previously Treated ES-SCLC Voluntarily Withdrawn October 1, 2026
Perioperative Imfinzi plus neoadjuvant enfortumab vedotin granted Priority Review in the US for MIBC patients October 1, 2026
